Unit Dose Budesonide (UDB): MAP Pharma’s Pediatric Asthma Drug Candidate, Passed Phase 2 Clinical Trial
MAP Pharmaceuticals, Inc.’s drug candidate - Unit Dose Budesonide (UDB) - is a proprietary nebulized formulation of budesonide for treatment of pediatric asthma.
In a U.S. based Phase 2 clinical trial UDB met its primary efficacy endpoints.
The primary endpoints for the study were asthma control as assessed by changes in morning asthma symptom scores compared to placebo, and trends in Forced Expiratory Volume in one second (FEV1). No serious adverse events were reported in the study, and UDB was shown to be well tolerated.
For more than 20 years of usage, Budesonide is a drug that has demonstrated safety and efficacy.
Unit Dose Budesonide (UBD), its nebulized formulation, is intended to provide efficacy at a lower overall corticosteroid dose than currently commercially available products.
Find more details from the press release.
There are treatments that can help, and each person responds to the disease differently. What can you expect? That depends on many factors.How advanced your rheumatoid arthritis is at the time you are diagnosed, your age at the time you are diagnosed or how "active" your disease is.
Posted by: narconon drug rehab | November 5, 2007 7:31 AM | Permalink to Comment